About CDER - Report

CDER Report to the Nation: 2000

Table of Contents

International Activities

Index

• Mission
• Highlights
• International Conference on Harmonization
• Harmonization initiative in the Americas
• U.S.-European Union Mutual Recognition Agreement
• Internet sources

Mission

We participate through appropriate processes with representatives of other countries to reduce the burden of regulation, harmonize regulatory requirements and achieve appropriate reciprocal arrangements.

Highlights from 2001 include:

• Accepting the first new drug applications in the Common Technical Document format. The CTD can be used for seeking approval to market new drugs in the United States, the European Union and Japan.
• Nearing completion of the electronic CTD.
• Prioritizing issues for our harmonization efforts among the countries of North and South America.
• Leadership of the U.S. consultations with the European Union to allow for reciprocal reliance on manufacturing plant inspections.
• Exchanging recall information and alerts concerning significant emerging product quality problems with the European Union.

International Conference on Harmonization

Harmonization-making the drug regulatory processes more efficient and uniform-is an issue that is important not only to Americans, but to drug regulatory agencies and pharmaceutical companies throughout the world. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use has worked to bring together government regulators and drug industry experts from innovator trade associations in the European Union, Japan and the United States.

We are leading the FDA's collaboration with the ICH. This work will help make new drugs available with minimum delays not only to American consumers but also to patients in other parts of the world.

The drug regulatory systems in all three regions share the same fundamental concerns for the safety, efficacy and quality of drug products. Before ICH, many time-consuming and expensive technical tests had to be repeated in all three regions. The ICH goal is to minimize unnecessary duplicate testing during the research and development of new drugs. The ICH process results in guidance documents that create consistency in the requirements for product registration.

Common Technical Document update

The ICH Common Technical Document allows data in the same format to be submitted to drug review authorities in all three ICH regions.

• We have received five new drug submissions in CTD format, several for new dosage forms. Some submissions use paper for some sections and electronic media for others.
• Work on making the document suitable for electronic submission is nearing completion.

Harmonization initiative in the Americas

We are working with the Pan American Health Organization to promote regulatory harmonization within the Americas. PAHO is part of the United Nations system, serving as the World Health Organization's regional office for the Americas. The initiative, called the Pan American Network for Drug Regulatory Harmonization or PANDRH, will search for common ground on various topics in a prioritized work plan.

We are the lead for two topics of high priority-good manufacturing practices and bioequivalence. We are working with the countries of Latin America to provide training on these two important issues. Training to the same standards should help lead to harmonization. Other urgent issues are good clinical practices and counterfeit drugs.

U.S.-European Union Mutual Recognition Agreement

This agreement provides for reciprocal reliance on inspection systems in the United States and each of the 15 member nations of the European Union. The globalization of the pharmaceutical industry is outpacing our resources to inspect pharmaceutical manufacturing plants worldwide. Once fully implemented, the agreement will allow us to base our regulatory decisions on inspection data from "equivalent authorities" in the European Union. Equivalent authorities are those with regulatory systems for good manufacturing practices that we have assessed and determined will achieve a comparable level of public health protection.

While the agreement will allow us to use an inspection report from one of our European counterparts as though it were our own, the actual regulatory decision will be up to us. Our experts in good manufacturing practices are leading the FDA team that is working with a team from the European Union to implement this agreement.

MRA update

A planned three-year transition to full implementation has not proceeded as smoothly as anticipated, but both parties remain optimistic

• Last year, we began exchanging recall information and alerts concerning significant emerging product quality problems.
• We proposed exchanging inspection reports on a pilot basis and audited the first E.U. member state.
• A team of E.U. officials audited our regulatory system for good manufacturing practices with a positive outcome.

Internet sources

• More information about our international activities, including Spanish language materials, is at http://www.fda.gov/cder/audiences/iact/iachome.htm.
• We have published ICH documents as guidances to industry. These are on our Web site at http://www.fda.gov/cder/guidance/index.htm.
• PAHO information is at http://www.paho.org. Information on PANDRH is at http://www.paho.org/english/gov/cd/cd42_13-e.pdf.
• The Mutual Recognition Agreement is at http://www.mac.doc.gov/mra/mra.htm.

Back to Index

Back to Contents

Next Page

Back to Top   Back to About CDER

FDA/Center for Drug Evaluation and Research
Last Updated: June 21, 2005
Originator: OTCOM/DCM
HTML by JO, PKS